Navigation Links
Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
Date:12/14/2007

SHANGHAI, China, Dec. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that Governor Deval L. Patrick of the Commonwealth of Massachusetts, accompanied by other members of Massachusetts China Partnership Official Delegation, paid a visit to the company on December 7 in Shanghai, China.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Massachusetts China Partnership Official Delegation visitors included representatives from Massachusetts life science industry and academia such as Joshua Schafer Boger, Chief Executive Officer of Vertex Pharmaceuticals, and Jack Martin Wilson, President of University of Massachusetts.

Massachusetts is the U.S.'s epicenter for biotechnology, with over 300 biopharmaceutical companies located in the state. With the intellectual resources of leading universities and healthcare institutions, biotechnology has become one of the most important industries in Massachusetts.

During the meeting between the honorable guests and the management team of the company, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, gave Governor Patrick a brief introduction of the company and hoped for more collaboration opportunities between the two parties for continued expansion of the biopharmaceutical industry.

"I am here to encourage the collaboration that WuXi PharmaTech has with Massachusetts companies such as Vertex, and with enterprises everywhere that have the interest and ability to contribute to the future of healing," commented Governor Patrick in his address. "This collaboration has benefits for both Massachusetts and China, and for the future of health care all over the world. Working together, we will be stronger and more successful than we ever could be working apart."

The Governor added, "As in the United States, China's population is aging and life science is helping to alleviate suffering and improve quality of life for so many. By helping to find new treatments and cures while lowering health care system cost, life science gives us the opportunity to do well while doing good."

Commenting on the delegation's visit, Joshua Boger, Vertex Pharmaceuticals CEO and official delegation member said, "Through our over four years of cooperation, WuXi PharmaTech has become a trusted and important partner for our business. A trip to WuXi PharmaTech is a must-do for any life sciences company visiting China."

As China's leading provider of pharmaceutical R&D outsourcing services, WuXi PharmaTech helps more than 20 Massachusetts pharmaceutical and biotech companies accelerate their drug discovery from idea to market.

"We are much honored to host Governor Patrick and his delegation. WuXi PharmaTech has cultivated deep relationships with the financial and life science industries in Massachusetts. With the trust from our customers and support from the government, we look forward to serving more pharma and biotech companies in Massachusetts," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech.

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies with a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services; and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to over 80 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-50464002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. AG Mednet Selected By Massachusetts General Hospital to Transport 3D Post-Processing Images
3. 2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies
4. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
5. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
6. WuXi PharmaTech Announces Second Quarter 2007 Results
7. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
8. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Oxford Gene Technology ... NGS panel range with the launch of the SureSeq myPanel™ ... of variants in familial hypercholesterolemia (FH). The panel delivers single ... a single small panel and allows customisation by ,mix and ... exons for LDLR , P C ...
(Date:12/8/2016)... Worcester, Mass (PRWEB) , ... December 08, 2016 ... ... KbioBox genetic data bioInformatics portal. In response to client demand KbioBox developed a ... gene edit biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we ... of recovery so we need to do it well. Inadequate sleep levels have been ... blood pressure, stroke, diabetes, and even cancer. Maybe now is the best ... that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):